Common and serious GLP-1 side effects

What this page covers

GLP-1 medicines used for weight management, including semaglutide products such as Wegovy and Ozempic and tirzepatide products such as Zepbound and Mounjaro, change appetite and slow how quickly the stomach empties. Those actions help many trial participants lose weight when the medicine is combined with a reduced-calorie diet and more physical activity. The same actions also explain why stomach and bowel symptoms are so common.

This guide summarizes what FDA-approved labels and large trials report about side effects. It is educational, not medical advice, and it is not a diagnosis. A licensed clinician is the only person who can interpret symptoms for a specific patient. Beema Health does not sell branded GLP-1 products on this marketing site. When a provider prescribes treatment after a medical intake, that decision is individualized and is never guaranteed.

How GLP-1 medicines produce side effects

GLP-1 receptor agonists mimic a gut hormone that signals fullness in the brain and slows gastric emptying. Tirzepatide also activates the GIP receptor. Delayed emptying can cause nausea, bloating, reflux, and early fullness. Reduced intake can leave people dehydrated or under-fueled, which may contribute to dizziness, constipation, fatigue, or hair shedding.

Most labeled common reactions are gastrointestinal. In Wegovy adult weight-reduction trials, 73% of treated patients reported GI adverse reactions versus 47% on placebo, and severe GI reactions were more frequent with treatment (4.1% versus 0.9%). Permanent discontinuation because of a GI reaction occurred in 4.3% of Wegovy-treated adults versus 0.7% on placebo. Those figures describe averages in trials, not a promise that symptoms will be mild.

Common effects reported in trials

Wegovy labeling lists nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in people with type 2 diabetes, flatulence, gastroenteritis, reflux, and hair loss among reactions seen in 5% or more of adults or adolescents. Zepbound labeling lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and reflux in 5% or more of treated patients.

Dose and timing matter. In SURMOUNT-1, nausea ranged from about 25% to 33% depending on tirzepatide dose. In pooled STEP 1 through 3 data, nausea occurred in 43.9% of people on semaglutide 2.4 mg versus 16.1% on placebo. Many GI events clustered around titration. Injection-site reactions were more frequent with tirzepatide than placebo, especially in people who developed anti-tirzepatide antibodies.

• Nausea, vomiting, diarrhea, and constipation are the most reported GI effects.
• Fatigue, dizziness, bloating, and hair loss also appear in approved labels.
• Injection-site redness, itching, or swelling is more prominent in tirzepatide trials.
• Symptoms often peak when the dose is increased, then may ease - they do not always.

Serious risks that labels do not minimize

FDA-approved GLP-1 and dual GIP/GLP-1 products carry a boxed warning for thyroid C-cell tumors seen in rodents. It is not known whether those tumors, including medullary thyroid carcinoma, occur in humans. These medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Labels also warn about pancreatitis, gallbladder problems (including gallstones and inflammation), acute kidney injury related to vomiting or diarrhea, severe gastrointestinal reactions, hypoglycemia with insulin or sulfonylureas, diabetic retinopathy complications in some people with type 2 diabetes, and serious hypersensitivity. FDA has updated GLP-1 class labeling for pulmonary aspiration during procedures that require general anesthesia or deep sedation, because delayed gastric emptying can leave food in the stomach.

Postmarketing reports for semaglutide include ileus, intestinal obstruction, and severe constipation including fecal impaction. Those events are uncommon relative to everyday nausea, but they are not theoretical. Persistent vomiting, severe constipation with no bowel movement, or a swollen, painful abdomen needs prompt clinical evaluation rather than home troubleshooting.

When to seek medical care

Contact a clinician promptly for vomiting or diarrhea that prevents keeping fluids down, dizziness with fainting, a sudden drop in urine output, yellowing of the skin or eyes, right-upper-quadrant pain, or a rash with swelling of the face or throat. Severe abdominal pain that radiates to the back, with or without vomiting, can be a pancreatitis warning and is an emergency until proven otherwise.

Tell surgeons and anesthesiologists about GLP-1 treatment before any procedure. Do not stop or skip doses based on an article. A licensed clinician decides whether to pause treatment, slow titration, add supportive care, or switch medicines. People who use insulin or a sulfonylurea need a plan for low blood sugar, because GLP-1 treatment can increase that risk when those drugs are combined.

• Emergency care: severe abdominal pain, allergic swelling, chest pain, fainting, or inability to drink.
• Same-day clinician contact: persistent vomiting, little or no urine, black stools, or worsening jaundice.
• Planned procedures: disclose GLP-1 use so the care team can manage aspiration risk.

What clinicians often review if symptoms appear

A clinician typically reviews how the dose was increased, other medicines, hydration, protein and fiber intake, injection technique, and warning symptoms that would require labs or imaging. Slowing titration is a labeled strategy when GI effects are not tolerated. Holding at a lower dose is sometimes used; that is a clinical judgment, not a do-it-yourself protocol.

Lifestyle context still matters. GLP-1 treatment for weight management is indicated as an adjunct to a reduced-calorie diet and increased activity, not as a stand-alone guarantee of weight change. If nausea is so intense that eating collapses, or constipation becomes severe, the priority is safety, not pushing through for faster weight loss. Related articles on this site cover individual symptoms in more depth.

How this relates to medical weight-loss care

People researching GLP-1 treatment often want a clear picture of tradeoffs before talking with a clinician. That is a reasonable use of educational pages. Appropriateness still depends on BMI criteria in labeling, medical history, other medicines, pregnancy plans, and contraindications. A prescription is never automatic after an online questionnaire.

If you are comparing program options, start with how care is structured: licensed provider review, follow-up, and a plan for side effects. Beema Health's medical weight-loss pages describe telehealth intake. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. The same is true of compounded tirzepatide. Those product pages are separate from this class-level safety overview.

Frequently asked questions

Sources

1. [1] Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. DailyMed.
2. [2] Zepbound (tirzepatide) injection Prescribing Information. Eli Lilly. DailyMed.
3. [3] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
4. [4] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
5. [5] Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2021.
6. [6] Wegovy (semaglutide) injection. FDA prescribing information: Warnings and Precautions, pulmonary aspiration during general anesthesia or deep sedation.